Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

Overview of attention for article published in Journal for Immunotherapy of Cancer, April 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 13 X users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 14 X posts from 13 X users, with an upper bound of 48,592 followers.

RT @jitcancer: New #JITC article: Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple mye…

RT @HJChoMDPhD1: Great work by @NeoSelma and @TischCancer #mmsm MM Center of Excellence clinical research team in collaboration with David…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.